Symbol | Exchange | Currency |
|---|
Investing.com - Surface Oncology (NASDAQ: SURF) reported first quarter EPS of $-0.350, $0.03 worse than the analyst estimate of $-0.322. Revenue for the quarter came in at $0.00...
Surface Oncology (Nasdaq: NASDAQ:SURF) reported financial results and corporate highlights for the first quarter of 2022 as well as upcoming anticipated corporate milestones. “The...
The beginning of earnings season can be a nerve-wracking time for investors, so it’s as good a time as any for stocks to finally take a break after four days of solid...
New Zacks Feature: ASK ALEXA Now call out a stock name or ticker. Alexa will give you its latest Zacks Rank and price. Also hear daily additions to and deletions from the...
It’ll be tough for September to repeat the impressive successes of August… but it sure did get off to a good start on Tuesday. It might be a new month, but...
Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibody that inhibits CD39 enzymatic activity for the production of adenosine and the breakdown of adenosine triphosphate; SRF388 which is in phase II clinical trial targeting interleukin 27; GSK4381562, an antibody targeting CD112R, an inhibitory protein expressed on natural killer and T cells; and SRF114 that is in phase 1/2 clinical trials targeting the chemokine receptor CCR8. Surface Oncology, Inc. has a license agreement with GlaxoSmithKline Intellectual Property (No. 4) Limited and Vaccinex, Inc. to develop, manufacture, and commercialize antibodies, which targets SRF114. The company was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
| Average | 5.400 (+770.968% Upside) |
| High | 6.000 |
| Low | 3.000 |
| Price | 0.620 |
| No. of Analysts | 5 |
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Sell | Strong Sell | Sell | Strong Sell | Strong Sell |
| Technical Indicators | Strong Sell | Strong Sell | Strong Sell | Strong Sell | Strong Sell |
| Summary | Strong Sell | Strong Sell | Strong Sell | Strong Sell | Strong Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 190.41 | 192.36 | 187.15 | -1.81 | -0.94% | 115.62M | NASDAQ | |||
| 160.25 | 160.34 | 157.85 | +1.32 | +0.83% | 56.97M | NASDAQ | |||
| 60.90 | 61.01 | 59.91 | +0.98 | +1.64% | 12.65M | NYSE | |||
| 206.01 | 207.58 | 203.55 | +1.73 | +0.85% | 27.63M | NASDAQ | |||
| 105.44 | 105.49 | 103.84 | -0.16 | -0.15% | 30.02M | NASDAQ | |||
| 280.57 | 280.63 | 275.28 | +2.91 | +1.05% | 28.01M | NASDAQ | |||
| 40.39 | 40.46 | 39.87 | +0.21 | +0.52% | 17.13M | NYSE | |||
| 97.95 | 99.52 | 96.74 | -2.33 | -2.32% | 64.14M | NASDAQ | |||
| 98.13 | 98.30 | 96.40 | -0.58 | -0.59% | 55.74M | NASDAQ | |||
| 156.56 | 158.27 | 153.56 | -3.42 | -2.14% | 2.51M | NASDAQ | |||
| 267.79 | 271.67 | 263.55 | -4.12 | -1.52% | 45.08M | NASDAQ | |||
| 8.20 | 8.35 | 8.06 | -0.13 | -1.56% | 17.87M | NYSE | |||
| 106.07 | 106.16 | 104.74 | -0.18 | -0.17% | 25.05M | NASDAQ | |||
| 44.98 | 45.58 | 44.24 | -0.81 | -1.77% | 11.13M | NYSE | |||
| 50.51 | 50.55 | 49.49 | +0.78 | +1.57% | 19.26M | NASDAQ |